Vertex Announces Participation in UBS Global Healthcare Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its leadership will participate in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer of Vertex, is scheduled to take part in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. Eastern Time. The event underscores Vertex’s ongoing commitment to engaging with investors and sharing insights into its scientific programs and business strategy.
What to Expect from the Conference Appearance
The fireside chat will be a key opportunity to hear directly from Vertex’s leadership about the company’s progress across its approved therapies and its robust clinical pipeline. Vertex continues to focus on transformative medicines for serious diseases, including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also has a broad investigational portfolio across modalities and disease areas, highlighted by its deep understanding of causal human biology.
Leadership Panel and Key Topics
During the presentation, CEO Reshma Kewalramani is expected to address Vertex’s evolving strategy in rare diseases and chronic conditions, the status of ongoing clinical programs, and ongoing efforts to accelerate innovation while maintaining a strong patient-centric focus. Investors will be looking for updates on pipeline advancement, collaboration opportunities, and Vertex’s approach to balancing near-term milestones with long-term growth.
How to Access the Vertex Presentation
A live webcast of Vertex management’s remarks will be available on the company’s website, www.vrtx.com, in the Investors section under News and Events. A replay of the conference webcast will be archived on Vertex’s site for those who cannot attend the live session. This accessibility supports Vertex’s broader commitment to transparent communication with shareholders and potential investors around major corporate events.
About Vertex
Vertex is a global biotechnology company built on scientific innovation aimed at delivering transformative medicines for people with serious diseases. The company’s approved therapies address conditions including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Vertex maintains a dynamic clinical pipeline across several modalities and disease areas, with a focus on conditions where deep biology can unlock meaningful therapeutic advances. Vertex’s research and development footprint spans North America, Europe, Australia, Latin America, and the Middle East, with its global headquarters in Boston and international headquarters in London.
Vertex’s Position in the Biotech Landscape
Beyond its approved medicines, Vertex actively pursues clinical programs in areas such as neuropathic pain, kidney diseases, IgA nephropathy, nephrotic and hepatic conditions, and metabolic disorders. The company’s strategy emphasizes precision medicine and targeted therapies that aim to improve patient outcomes while expanding access to innovative treatments. Vertex has repeatedly been recognized as a leader in corporate culture and innovation, including years on respected industry rankings for work environment and corporate excellence.
Conclusion
As Vertex participates in the UBS Global Healthcare Conference, investors will gain valuable perspective on the company’s milestones, strategic priorities, and long-term potential. The fireside chat with Reshma Kewalramani represents a chance to hear firsthand how Vertex intends to advance its mission of delivering transformative medicines for people with serious diseases while navigating the evolving biopharma landscape.
